Literature DB >> 22561155

BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.

Pia Dosenovic1, Martina Soldemo, Jean L Scholz, Sijy O'Dell, Emilie K Grasset, Nadège Pelletier, Mikael C I Karlsson, John R Mascola, Richard T Wyatt, Michael P Cancro, Gunilla B Karlsson Hedestam.   

Abstract

Neutralizing Abs provide the protective effect of the majority of existing human vaccines. For a prophylactic vaccine against HIV-1, broadly neutralizing Abs targeting conserved epitopes of the viral envelope glycoproteins (Env) are likely required, because the pool of circulating HIV-1 variants is extremely diverse. The failure to efficiently induce broadly neutralizing Abs by vaccination may be due to the use of suboptimal immunogens or immunization regimens, or it may indicate that B cells specific for broadly neutralizing Env determinants are selected against during peripheral checkpoints, either before or after Ag encounter. To investigate whether perturbation of B cell subsets prior to immunization with recombinant Env protein affects the vaccine-induced Ab response in mice, we used B lymphocyte stimulator (BLyS), a cytokine that regulates survival and selection of peripheral B cells. We show that the transient BLyS treatment used in this study substantially affected naive B cell populations; in particular, it resulted in more B cells surviving counter-selection at the transitional stages. We also observed more mature naive B cells, especially marginal zone B cells, in BLyS-treated mice. Intriguingly, provision of excess BLyS prior to immunization led to a consistent improvement in the frequency and potency of HIV-1 Env vaccine-induced neutralizing Ab responses, without increasing the number of Env-specific Ab-secreting cells or the Ab-binding titers measured after boosting. The results presented in this article suggest that an increased understanding of BLyS-regulated processes may help the design of vaccine regimens aimed at eliciting improved neutralizing Ab responses against HIV-1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561155      PMCID: PMC3370119          DOI: 10.4049/jimmunol.1200466

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production.

Authors:  Susan L Kalled
Journal:  Semin Immunol       Date:  2006-08-22       Impact factor: 11.130

2.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

3.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.

Authors:  P A Moore; O Belvedere; A Orr; K Pieri; D W LaFleur; P Feng; D Soppet; M Charters; R Gentz; D Parmelee; Y Li; O Galperina; J Giri; V Roschke; B Nardelli; J Carrell; S Sosnovtseva; W Greenfield; S M Ruben; H S Olsen; J Fikes; D M Hilbert
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

5.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Authors:  Erin M Scherer; Michael B Zwick; Luc Teyton; Dennis R Burton
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

7.  Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7.

Authors:  Angela Malaspina; Susan Moir; Jason Ho; Wei Wang; Melissa L Howell; Marie A O'Shea; Gregg A Roby; Catherine A Rehm; Joann M Mican; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

8.  Most peripheral B cells in mice are ligand selected.

Authors:  H Gu; D Tarlinton; W Müller; K Rajewsky; I Förster
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

9.  Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.

Authors:  Susan Moir; Angela Malaspina; Oxana K Pickeral; Eileen T Donoghue; Joshua Vasquez; Natalie J Miller; Surekha R Krishnan; Marie A Planta; John F Turney; J Shawn Justement; Shyamasundaran Kottilil; Mark Dybul; JoAnn M Mican; Colin Kovacs; Tae-Wook Chun; Charles E Birse; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-09-06       Impact factor: 14.307

10.  Repertoire-based selection into the marginal zone compartment during B cell development.

Authors:  John B Carey; Chantelle S Moffatt-Blue; Lisa C Watson; Amanda L Gavin; Ann J Feeney
Journal:  J Exp Med       Date:  2008-08-18       Impact factor: 14.307

View more
  23 in total

1.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Authors:  Anirudh Saraswathula; Elizabeth A Reap; Bryan D Choi; Robert J Schmittling; Pamela K Norberg; Elias J Sayour; James E Herndon; Patrick Healy; Kendra L Congdon; Gerald E Archer; Luis Sanchez-Perez; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2016-01-12       Impact factor: 6.968

3.  Slc15a4 function is required for intact class switch recombination to IgG2c in response to TLR9 stimulation.

Authors:  Pia Dosenovic; Monika Ádori; William C Adams; Gabriel K Pedersen; Martina Soldemo; Bruce Beutler; Gunilla B Karlsson Hedestam
Journal:  Immunol Cell Biol       Date:  2014-10-14       Impact factor: 5.126

Review 4.  Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Frederick W Alt; Ming Tian
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 5.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

Review 6.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

Review 7.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

8.  Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.

Authors:  Mar Naranjo-Gomez; Jennifer Lambour; Marc Piechaczyk; Mireia Pelegrin
Journal:  JCI Insight       Date:  2018-05-03

9.  BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Authors:  Luis Sanchez-Perez; Bryan D Choi; Elizabeth A Reap; Elias J Sayour; Pamela Norberg; Robert J Schmittling; Gerald E Archer; James E Herndon; Duane A Mitchell; Amy B Heimberger; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2013-04-17       Impact factor: 6.968

10.  Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.

Authors:  Lindsey M Pujanauski; Edward N Janoff; Martin D McCarter; Roberta Pelanda; Raul M Torres
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.